
Spectrum Pharmaceuticals SPPI
Spectrum Pharmaceuticals Operating Expenses | SPPI
Annual Operating Expenses Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81 M | 148 M | 170 M | 141 M | 214 M | 178 M | 172 M | 176 M | 191 M | 166 M | 141 M | 104 M | 52.9 M | 28.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 214 M | 28.5 M | 140 M |
Quarterly Operating Expenses Spectrum Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.4 M | 11.6 M | 21.6 M | 25.4 M | 14.1 M | 36.9 M | 33.1 M | 44.1 M | 33.7 M | 62.9 M | 39.6 M | 36.5 M | 30.8 M | 38.4 M | 30.3 M | 34.2 M | 37.8 M | 46.5 M | 28.4 M | 33 M | 30 M | 41.1 M | 15.1 M | 18.6 M | 21.9 M | 17.9 M | 16.2 M | 22.3 M | 6.49 M | 2.96 M | 16.1 M | 34 K | 21.7 M | 1.63 M | 4.13 M | 1.4 M | 24.4 M | 6.51 M | 13.3 M | 12.5 M | 6.46 M | -11 M | -23.1 M | -23 M | -23.6 M | -9.66 M | -18 M | -9.92 M | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 62.9 M | -23.6 M | 17.5 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | ||
|
Zosano Pharma Corporation
ZSAN
|
33 K | - | 7.23 % | $ 2.72 M | ||
|
Alpine Immune Sciences
ALPN
|
103 M | - | - | $ 2.17 B | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Kaleido Biosciences
KLDO
|
88.8 M | - | -3.69 % | $ 12.4 M | ||
|
VBI Vaccines
VBIV
|
88.6 M | - | -50.87 % | $ 1.09 M | ||
|
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | ||
|
Decibel Therapeutics
DBTX
|
64 M | - | - | $ 123 M | ||
|
Arcutis Biotherapeutics
ARQT
|
352 M | $ 26.35 | -3.02 % | $ 3.35 B | ||
|
IVERIC bio
ISEE
|
190 M | - | - | $ 5.51 B | ||
|
ObsEva SA
OBSV
|
74.6 M | - | -15.52 % | $ 10.5 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
1.16 B | $ 41.53 | -4.86 % | $ 5.88 B | ||
|
Monopar Therapeutics
MNPR
|
16.7 M | $ 69.02 | -1.81 % | $ 512 M | ||
|
Poseida Therapeutics
PSTX
|
194 M | - | - | $ 857 M | ||
|
Y-mAbs Therapeutics
YMAB
|
138 M | - | - | $ 382 M | ||
|
Satsuma Pharmaceuticals
STSA
|
70.9 M | - | -0.9 % | $ 36.5 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 0.59 | -11.3 % | $ 50.3 M | ||
|
SpringWorks Therapeutics
SWTX
|
457 M | - | - | $ 3.48 B | ||
|
Axon Enterprise
AXON
|
1.72 B | $ 291.02 | -5.2 % | $ 22.7 B | ||
|
Infinity Pharmaceuticals
INFI
|
47.4 M | - | -46.98 % | $ 3.57 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Evelo Biosciences
EVLO
|
108 M | - | -14.46 % | $ 27.9 M | ||
|
Morphic Holding
MORF
|
64 M | - | - | $ 2.42 B | ||
|
Genocea Biosciences
GNCA
|
53.7 M | - | -15.0 % | $ 3.04 M | ||
|
Biogen
BIIB
|
7.49 B | $ 249.55 | 0.98 % | $ 36.6 B | ||
|
Bristol-Myers Squibb Company
BMY
|
34.3 B | $ 58.74 | 0.69 % | $ 119 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
62.1 M | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
211 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
2.04 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
178 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
772 M | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
10.6 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
159 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
61.4 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
120 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
95.1 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
185 M | - | - | $ 2.6 B | ||
|
Syros Pharmaceuticals
SYRS
|
139 M | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
8.31 M | $ 1.15 | -2.54 % | $ 23.2 M | ||
|
GT Biopharma
GTBP
|
13.6 M | $ 2.93 | -7.86 % | $ 16.2 M | ||
|
Zymeworks
ZYME
|
53.2 M | $ 26.41 | -1.68 % | $ 1.36 B | ||
|
Aldeyra Therapeutics
ALDX
|
60.1 M | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
38.5 M | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
700 M | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
153 M | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
86.4 M | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
1.36 B | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 13.09 | -2.68 % | $ 374 M |